Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

Yes, all outcome measure should be in the registry at clinicaltrials.gov. In practise companies do have much leeway when and what do they provide.

see: https://www.statnews.com/2017/01/17/clinical-trial-reporting-new-rule/

And no, I don't expect B-OM phase 3 to have cancer survival component. Galera's interest is a results of some studies showing hydrogen peroxide inhibiting tumor growth. GC4419 presumably converts radiation produced super oxides (oxygen diatom with one electron knocked off by radiation, I guess) to hydrogen peroxide. Hence Galera's interest. Also, Galera had survival analysis included in the protocol of GC4419 phase 2 trial, which is still ongoing.

see: https://clinicaltrials.gov/ct2/show/NCT02508389?term=GC4419&rank=3

Brilacidin has not (yet ??) shown similar effect on cancer as far as I know.